Cargando…

Poor prognosis of intra‐tumoural TRBV6‐6 variants in EGFR‐mutant NSCLC: Results from the ADJUVANT‐CTONG1104 trial

Detalles Bibliográficos
Autores principales:	Chen, Cunte, Liu, Siyang Maggie, Chen, Yedan, Han, Ming, Ou, Qiuxiang, Bao, Hua, Xu, Ling, Zhang, Yikai, Zhang, Jia‐Tao, Zhong, Wenzhao, Zhou, Qing, Yang, Xue‐Ning, Shao, Yang, Wu, Yi‐Long, Liu, Si‐Yang, Li, Yangqiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029017/ https://www.ncbi.nlm.nih.gov/pubmed/35452192 http://dx.doi.org/10.1002/ctm2.775

Ejemplares similares

Predictive value of TCR Vβ-Jβ profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial
por: Chen, Cunte, et al.
Publicado: (2022)

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial
por: Zhong, Wen-Zhao, et al.
Publicado: (2021)

Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer
por: Liu, Si-Yang Maggie, et al.
Publicado: (2023)

Frequency analysis of TRBV subfamily sjTRECs to characterize T-cell reconstitution in acute leukemia patients after allogeneic hematopoietic stem cell transplantation
por: Wu, Xiuli, et al.
Publicado: (2011)

Compositional characteristics of human peripheral TRBV pseudogene rearrangements
por: Shi, Bin, et al.
Publicado: (2018)

Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC
por: Wang, Jinguang, et al.
Publicado: (2018)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
por: Zhang, Zhonghan, et al.
Publicado: (2019)

Worldwide genetic variation of the IGHV and TRBV immune receptor gene families in humans
por: Luo, Shishi, et al.
Publicado: (2019)

Targeted depletion of TRBV9(+) T cells as immunotherapy in a patient with ankylosing spondylitis
por: Britanova, Olga V., et al.
Publicado: (2023)

Results and Complications of 1104 Surgeries for Velopharyngeal Insufficiency
por: Hirschberg, Jenő
Publicado: (2012)

1104. Antibiotic Prophylaxis for the Endoscopic Endonasal Approach
por: DeKerlegand, Alaina, et al.
Publicado: (2019)

Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTONG1304)
por: Song, Yong, et al.
Publicado: (2019)

Profiling of Peripheral TRBV and CD4+CD25+ Treg in CHB Patients with HBeAg SC during TDF Treatment
por: Yang, Jiezuan, et al.
Publicado: (2023)

Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes
por: Zhao, Weixin, et al.
Publicado: (2023)

The importance of genomic predictors for clinical outcome of hematological malignancies
por: Chen, Cunte, et al.
Publicado: (2021)

Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial
por: Zhong, Wen-Zhao, et al.
Publicado: (2023)

Low Expression of CD5 and CD6 Is Associated with Poor Overall Survival for Patients with T-Cell Malignancies
por: Sui, Songnan, et al.
Publicado: (2022)

Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients
por: Su, Jian, et al.
Publicado: (2017)

Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial
por: Maggie Liu, Si-Yang, et al.
Publicado: (2023)

The superantigens SpeC and TSST-1 specifically activate TRBV12-3/12-4(+) memory T cells
por: Shepherd, Freya R., et al.
Publicado: (2023)

Network for Development of Electroporation-Based Technologies and Treatments: COST TD1104
por: Miklavčič, Damijan
Publicado: (2012)

Draft Genome Sequence of Agrobacterium fabrum Strain 1D1104
por: Huo, Naxin, et al.
Publicado: (2021)

Disulfiram, an aldehyde dehydrogenase inhibitor, works as a potent drug against sepsis and cancer via NETosis, pyroptosis, apoptosis, ferroptosis, and cuproptosis
por: Nie, Dingrui, et al.
Publicado: (2022)

The Chinese Thoracic Oncology Group (CTONG) therapeutic option scoring system: a multiple-parameter framework to assess the value of lung cancer treatment options
por: Cui, Jiu-Wei, et al.
Publicado: (2021)

Immediate Adaptation Analysis Implicates BCL6 as an EGFR-TKI Combination Therapy Target in NSCLC
por: Zhou Tran, Yan, et al.
Publicado: (2020)

Age-Related Immune Profile of the T Cell Receptor Repertoire, Thymic Recent Output Function, and miRNAs
por: Xu, Yan, et al.
Publicado: (2020)

Association between the XPG Asp1104His and XPF Arg415Gln Polymorphisms and Risk of Cancer: A Meta-Analysis
por: He, Xiao-Feng, et al.
Publicado: (2014)

FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth
por: Niu, Mengmeng, et al.
Publicado: (2021)

Inhibition of Tumor Lymphangiogenesis is an Important Part that EGFR-TKIs Play in the Treatment of NSCLC
por: Zhang, Yan, et al.
Publicado: (2020)

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
por: He, Qihua, et al.
Publicado: (2021)

Vacuum Stability in Test Section 333, (Run 1104, 19th March 1980)
por: Mathewson, A G
Publicado: (1980)

Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV)
por: Xu, Chong-Rui, et al.
Publicado: (2023)

The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC
por: Yang, Yang, et al.
Publicado: (2017)

Combination of EGFR-TKIs and Chemotherapy as First-Line Therapy for Advanced NSCLC: A Meta-Analysis
por: OuYang, Pu-Yun, et al.
Publicado: (2013)

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs
por: Zhang, Chengjuan, et al.
Publicado: (2017)

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017)

Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S
por: Wei, Yang, et al.
Publicado: (2021)

Sulforaphane attenuates EGFR signaling in NSCLC cells
por: Chen, Chi-Yuan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_e0icnpllfo9suulcquqkvjl3uq